Anti-amyloid Therapy of Alzheimer’s Disease: Current State and Prospects
- Авторы: Kozin S.1, Barykin E.1, Mitkevich V.1, Makarov A.1
-
Учреждения:
- Engelhardt Institute of Molecular Biology
- Выпуск: Том 83, № 9 (2018)
- Страницы: 1057-1067
- Раздел: Review
- URL: https://journals.rcsi.science/0006-2979/article/view/151713
- DOI: https://doi.org/10.1134/S0006297918090079
- ID: 151713
Цитировать
Аннотация
Drug development for the treatment of Alzheimer’s disease (AD) has been for a long time focused on agents that were expected to support endogenous β-amyloid (Aβ) in a monomeric state and destroy soluble Aβ oligomers and insoluble Aβ aggregates. However, this strategy has failed over the last 20 years and was eventually abandoned. In this review, we propose a new approach to the anti-amyloid AD therapy based on the latest achievements in understanding molecular causes of cerebral amyloidosis in AD animal models.
Ключевые слова
Об авторах
S. Kozin
Engelhardt Institute of Molecular Biology
Email: mitkevich@gmail.com
Россия, Moscow, 119991
E. Barykin
Engelhardt Institute of Molecular Biology
Email: mitkevich@gmail.com
Россия, Moscow, 119991
V. Mitkevich
Engelhardt Institute of Molecular Biology
Автор, ответственный за переписку.
Email: mitkevich@gmail.com
Россия, Moscow, 119991
A. Makarov
Engelhardt Institute of Molecular Biology
Email: mitkevich@gmail.com
Россия, Moscow, 119991